Preparing for an Investigational New Drug (IND) application represents a key milestone for First-In-Human (FIH) studies. For many drug developers, especially those newer to the field, navigating this process can be complex. To simplify this journey, we dive into the...
Blog
Scantox continues its growth journey with the acquisition of Solural Pharma
Scantox A/S (“Scantox”) announces the acquisition of Solural Pharma (“Solural”) in Denmark. Scantox is the leading Nordic GLP-compliant pre-clinical contract research organization (“CRO”), headquartered in Denmark and since 2021 owned by Impilo. Solural has strong...